Global Amikacin (CAS 37517-28-5) Market Size By Type (98% Purity Type,99% Purity Type), By Application (Amikacin Eye Drops, Amikacin Injection), By Region, And Segment Forecasts, 2023 to 2032

The Global Amikacin (CAS 37517-28-5) Market was valued at USD 985 million in 2023 and is projected to reach USD 1.53 billion by 2031, growing at a CAGR of 5.8% during the forecast period of 2023–2031. Amikacin, a potent aminoglycoside antibiotic, is widely used in treating severe bacterial infections, particularly those caused by Gram-negative organisms. The rising incidence of hospital-acquired infections, growing prevalence of multidrug-resistant bacterial strains, and increased utilization in critical care settings are major factors driving the demand for Amikacin across global healthcare markets.

Drivers:

1. Rising Prevalence of Antimicrobial-Resistant Infections:

With a surge in drug-resistant infections globally, particularly in healthcare settings, Amikacin has become a critical solution due to its effectiveness against resistant Gram-negative bacteria.

2. Increased Surgical Procedures and ICU Admissions:

The growing number of surgeries and intensive care admissions requires robust infection control measures, boosting the clinical demand for injectable antibiotics like Amikacin.

3. Expanding Geriatric Population:

Elderly populations are more susceptible to infections and hospitalizations, contributing to the rising demand for parenteral antibiotics, including Amikacin.

Restraints:

1. Toxicity Concerns:

Nephrotoxicity and ototoxicity remain significant side effects of aminoglycosides, including Amikacin, which can limit long-term or high-dose use, particularly in vulnerable patient populations.

2. Emergence of Alternative Therapies:

The development and availability of newer broad-spectrum antibiotics and combination therapies are creating competitive pressure on the Amikacin market.

Opportunity:

1. Development of Liposomal and Inhalation-Based Formulations:

Emerging formulations, such as liposomal Amikacin for inhalation, are expanding its applications in treating lung infections, especially in cystic fibrosis and non-tuberculous mycobacterial (NTM) infections.

2. Market Expansion in Emerging Economies:

The rising burden of infectious diseases in developing countries and improvements in healthcare infrastructure present substantial opportunities for growth.

Market by System Type Insights:

Injectable Amikacin dominated the market in 2023, driven by its high usage in hospitals and emergency care for severe systemic infections. However, the Inhalation Formulation segment is gaining traction due to its effectiveness in targeted pulmonary drug delivery, offering a safer and more efficient treatment for chronic respiratory infections.

Market by End-use Insights:

The Hospital Pharmacy segment accounted for the largest market share in 2023. High dependency on hospitals for managing critical infections and the administration of IV antibiotics positions this segment as a key revenue contributor. The Online Pharmacy segment is expected to witness the fastest growth, fueled by rising e-commerce penetration and the shift toward home-based care.

Market by Regional Insights:

North America led the market in 2023 due to its advanced healthcare systems, high antibiotic prescription rates, and strong regulatory approvals. Asia-Pacific is expected to register the highest growth, with countries like India and China experiencing a growing burden of resistant infections, increasing healthcare access, and expanding antibiotic usage in both human and veterinary sectors.

Competitive Scenario:

Key players in the Global Amikacin Market include:

Bristol Myers Squibb

Pfizer Inc.

Teva Pharmaceutical Industries Ltd.

Sun Pharmaceutical Industries Ltd.

Hikma Pharmaceuticals PLC

Baxter International Inc.

Gland Pharma Ltd.

These companies are focusing on expanding production capacities, launching generic variants, and innovating new delivery formats to strengthen their market positions. For instance:

In 2023, Gland Pharma announced regulatory approval for its Amikacin injectable in multiple Southeast Asian markets.

Pfizer’s liposomal inhalation Amikacin continued expanding its indications, particularly in treating drug-resistant pulmonary infections.

Scope of Work – Global Amikacin (CAS 37517-28-5) Market

Key Market Developments:

2023: Teva launched a cost-effective Amikacin generic in Eastern Europe, increasing regional accessibility.

2024: Pfizer expanded FDA approval for its inhalation Amikacin product for additional indications.

2025: Hikma Pharmaceuticals began Phase II trials for a long-acting Amikacin formulation targeting severe pneumonia.

FAQs:

1) What is the current market size of the Global Amikacin (CAS 37517-28-5) Market?

The market size was valued at USD 985 million in 2023.

2) What is the major growth driver of the Global Amikacin (CAS 37517-28-5) Market?

The major growth driver is the rising prevalence of multidrug-resistant infections.

3) Which is the largest region during the forecast period in the Global Amikacin (CAS 37517-28-5) Market?

North America held the largest market share in 2023, while Asia-Pacific is projected to grow fastest.

4) Which segment accounted for the largest market share in the Global Amikacin (CAS 37517-28-5) Market?

The Injectable Amikacin segment accounted for the largest share.

5) Who are the key market players in the Global Amikacin (CAS 37517-28-5) Market?

Key players include Pfizer Inc., Teva Pharmaceutical, Sun Pharma, Hikma Pharmaceuticals, and Baxter International.